Natalya Narizhneva, PhD

***** ****** **., #*

Laguna Niguel, CA, 92677

716-***-**** (cell)

abn446@r.postjobfree.com

USA permanent resident

OBJECTIVE: a research Scientist / Principal scientist position

. 14-years research experience in biotechnology and academic research

settings

. 6-years of anti-cancer drug discovery experience in biotechnology company

. Experience in protein and small molecule drug development

. Experience in cellular and molecular assay development

. Experience in Protein Biochemistry / Biophysics

. Ability to plan and lead research project; analyze, summarize and present

experimental results

. Experience with SOP, protocols and reports writing

. Fifteen publications in peer-reviewed journals

Areas of Expertise

. Drug Discovery and Product Development: lead discovery and

optimization; cell-based assays; bioanalytical assays development;

small molecule screenings; biomarkers identification, PK/PD;

statistical data analysis and results interpretation.

. Protein Biochemistry / Biophysics, Analytical Techniques.

. Oncology and Molecular Cardiology.

. Cell Biology and Molecular Biology. Flow Cytometry.

. Protein expression, extraction, purification and characterization.

. Project Management; managing of outsourced experiments; SOP, study

report and protocol writing; oral and written communication.

. MS Office, Sigma Plot, Prizm, EndNote, Reference Manager, Adobe

Acrobat.

. Drug development and peer-review publication process.

Education

PhD, Biophysics - Russian Academy of Science, Institute of Protein

Research,

Pushchino, Russia (1998)

MS, Molecular Biology - Pushchino State University, Pushchino, Russia

(1995)

MS, Physics -, St. Petersburg University, St. Petersburg, Russia (1992)

Professional Experience

June 2006 - October 2011: Cleveland Biolabs, Inc., Cleveland, OH - Buffalo,

NY

Senior Scientist, R&D

. Project manager in anti-cancer department: based on small molecules

screening in cell-based assays a few compounds were selected which are

potent to inhibit cancer cells. I generated different type of assays

and SOPs; supervised junior scientists and technical staff; analyzed,

interpreted and presented data. These data were published in 2 peer-

reviewed journals. Provisional application was submitted ("Method for

treating androgen receptor positive cancers").

. Bioanalytical assays development.

. Analysis of pre-clinical animal data for radioprotection by CBLB502.

Reports writing.

. Biomarkers identification (currently used in a human safety study for

radioprotectant CBLB502). Analysis of pharmacodynamic profiles.

. In vitro investigation of molecular mechanisms of potential drugs.

. Animal protocols / reports writing.

. Coordination of CRO activities.

. Supervising and training of junior scientists and research associates.

. Investigation of molecular mechanisms of potential drugs.

September 2001 - June 2006: Cleveland Clinic Foundation, Cleveland, OH

Research Fellow

. Investigation of androgen receptor signaling in prostate cancer cells

(cell-based assays, high-throughput screenings). The work was done in

collaboration with Cleveland Biolabs, Inc.

. Identification of both functional and structural differences between

Thrombospondin-1 SNP: Asn-700 vs Ser-700 which is associated with

early onset of myocardial infarction. These data were published in 2

peer-reviewed journals.

February 2000 - August 2001: Case Western Reserve University, Cleveland, OH

Postdoctoral Fellow

. Investigation of alpha-crystallin folding with stop-flow technique.

. Expression and purification of alpha-crystallin in E.coli.

May 1998 - February 2000: Institute of Protein Research, Pushchino, Moscow

Region, Russia

Scientist

. Investigation of green fluorescent protein folding and alpha-

fetoprotein intermediate states using fluorescence-based techniques,

CD, calorimetry and chromatography. These data were published in 2

peer-reviewed journals.

Awards, Honors and Grants

1. American Heart Association Postdoctoral Fellow Grant: 2003-2005.

2. 2nd place for the Best Publication in Basic Science (Cleveland Clinic

Foundation), Lower Award 2005.

3. Winner of the F. Merlin Bumpus Award for Junior Investigator in Basic

Science (Cleveland Clinic Foundation), 2002.

4. J. Soros Predoctoral Fellowship Grant (for former Soviet Union

Republic): 1995, 1996, 1997.

References are available upon request

Publications:

1. Natalya Narizhneva, Natalia Tararova, Peter Ryabokon, Inna Shyshynova,

Anatoly Prokvolit, Pavel Komarov, Andrei Purmal, Andrei Gudkov,

Katerina Gurova. Small molecule screening reveals a transcription-

independent pro-survival function of androgen receptor in castration-

resistant prostate cancer. Cell Cycle 2009, 8(24): 4155-4167.

2. Natalia D. Tararova, Natalya V. Narizhneva, Vadim Krivokrysenko, Andrei

V. Gudkov, and Katerina V. Gurova. Prostate cancer cells tolerate a

narrow range of androgen receptor expression and activity. The

Prostate. 2007, 67(16): 1801-1815.

3. Natalya V. Narizhneva, Olga V. Razorenova, Eugene A. Podrez, Juhua

Chen, Unni M. Chandrasekharan, Paul E. DiCorleto, Edward F. Plow, Eric

J. Topol and Tatiana V. Byzova. Thrombospondin-1 upregulates expression

of cell adhesion molecules and promotes monocyte binding to

endothelium. FASEB Journal 2005, 19(9):1158-60.

4. Natalya V. Narizhneva, Vicky J. Byers-Ward, Martin J Quinn, Frank

Zidar, Edward F. Plow, Eric J. Topol and Tatiana V. Byzova. Molecular

and functional differences induced in thrombospondin-1 by the single

nucleotide polymorphism associated with the risk of premature, familial

myocardial infarction. J.Biol. Chem. 2004; 279(20): 216**-*****.

5. De S., Chen J., Narizhneva N.V., Heston W., Brainard J., Sage H. and

Byzova T.V. Molecular pathway for prostate cancer metastasis to bone.

J. Biol Chem. 2003; 278(40): 39044-50.

6. Tomashevski A.Yu., Melnik T.N., Narizhneva N.V., Shalovsky M.M.,

Vasiliev V.B. and Uversky V.N. The alpha-fetoprotein molecule has one

or two rigid domains depending on the protein purification procedure.

Protein and Peptide Lett. 1999; 6(4): 237-244.

7. Tomashevski A.Yu., Narizhneva N.V., Melnik T.N. and Uversky V.N. Alpha-

fetoprotein structure depends on the protein purification procedure:

further evidence on the structure forming role of the ligands. Protein

and Peptide Lett. 1998; 5(5): 295-301.

8. Narizhneva N.V, Uversky V.N. Decrease of dielectric constant transforms

the protein molecule into the molten globule state. Review.

Biochemistry (Moscow) 1998, 63(4): 448-455.

9. Uversky V.N, Narizhneva N.V. Effect of natural ligands on the

structural properties and conformational stability of proteins. Review.

Biochemistry (Moscow) 1998, 63(4): 420-433.

10. Uversky V.N, Narizhneva N.V, Ivanova T.V and Tomashevski A.Yu. Rigidity

of human alpha-fetoprotein tertiary structure is under ligand control.

Biochemistry. 1997; 36 (44):13638-45.

11. Uversky V.N., Narizhneva N.V., Kirschstein S.O., Winter S. and Lober G.

Conformational transitions provoked by organic solvents in beta-

lactoglobulin: can a molten globule like intermediate be induced by the

decrease in dielectric constant? Folding and Design. 1997; 2(3): 163-

72.

12. Narizhneva N.V., Ivanova T.V., Tomashevski A.Yu. and Uversky V.N.

Comparison of structural properties of homologous proteins human serum

albumin and alpha fetoprotein. Russian Journal of Molecular Biology

(Moscow) 1997; 31(6): 891-896.

13. Narizhneva N.V. and Uversky V.N. Human alpha-fetoprotein is in the

molten globule state under conditions modeling protein environment near

the membrane surface. Protein and Peptide Lett. 1997; 4: 243-249.

14. Uversky V.N., Narizhneva N.V., Ivanova T.V., Kirkitadze M.D.,

Tomashevski A.Yu. Ligand-free form of human alpha-fetoprotein: evidence

for the molten globule state. FEBS Lett. 1997; 410: 280-284.

15. Uversky V.N., Kirkitadze M.D., Narizhneva N.V., Potekhin S.A.,

Tomashevski A.Yu. Structural properties of alpha-fetoprotein from human

cord serum: the protein molecule at low pH possesses all the properties

of the molten globule. FEBS Lett. 1995; 364(2):165-167.

Contact this candidate